Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Analysis of Profitability Ratios 

Microsoft Excel

Profitability Ratios (Summary)

Celgene Corp., profitability ratios

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Return on Sales
Gross profit margin 96.15% 96.45% 96.08% 95.41% 94.90%
Operating profit margin 34.01% 36.28% 28.31% 24.61% 33.30%
Net profit margin 26.51% 22.66% 17.87% 17.49% 26.44%
Return on Investment
Return on equity (ROE) 65.67% 42.48% 30.29% 27.07% 30.65%
Return on assets (ROA) 11.40% 9.75% 7.12% 5.92% 11.53%

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Celgene Corp. gross profit margin ratio improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018 not reaching 2016 level.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Celgene Corp. operating profit margin ratio improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Celgene Corp. net profit margin ratio improved from 2016 to 2017 and from 2017 to 2018.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Celgene Corp. ROE improved from 2016 to 2017 and from 2017 to 2018.
ROA A profitability ratio calculated as net income divided by total assets. Celgene Corp. ROA improved from 2016 to 2017 and from 2017 to 2018.

Gross Profit Margin

Celgene Corp., gross profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Gross profit 14,678 12,512 10,747 8,741 7,178
Net product sales 15,265 12,973 11,185 9,161 7,564
Profitability Ratio
Gross profit margin1 96.15% 96.45% 96.08% 95.41% 94.90%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Gross profit margin = 100 × Gross profit ÷ Net product sales
= 100 × 14,678 ÷ 15,265 = 96.15%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Celgene Corp. gross profit margin ratio improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018 not reaching 2016 level.

Operating Profit Margin

Celgene Corp., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Operating income 5,191 4,707 3,167 2,255 2,519
Net product sales 15,265 12,973 11,185 9,161 7,564
Profitability Ratio
Operating profit margin1 34.01% 36.28% 28.31% 24.61% 33.30%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Operating profit margin = 100 × Operating income ÷ Net product sales
= 100 × 5,191 ÷ 15,265 = 34.01%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Celgene Corp. operating profit margin ratio improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018.

Net Profit Margin

Celgene Corp., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net income 4,046 2,940 1,999 1,602 2,000
Net product sales 15,265 12,973 11,185 9,161 7,564
Profitability Ratio
Net profit margin1 26.51% 22.66% 17.87% 17.49% 26.44%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Net profit margin = 100 × Net income ÷ Net product sales
= 100 × 4,046 ÷ 15,265 = 26.51%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Celgene Corp. net profit margin ratio improved from 2016 to 2017 and from 2017 to 2018.

Return on Equity (ROE)

Celgene Corp., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net income 4,046 2,940 1,999 1,602 2,000
Stockholders’ equity 6,161 6,921 6,599 5,919 6,525
Profitability Ratio
ROE1 65.67% 42.48% 30.29% 27.07% 30.65%
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
ROE = 100 × Net income ÷ Stockholders’ equity
= 100 × 4,046 ÷ 6,161 = 65.67%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Celgene Corp. ROE improved from 2016 to 2017 and from 2017 to 2018.

Return on Assets (ROA)

Celgene Corp., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net income 4,046 2,940 1,999 1,602 2,000
Total assets 35,480 30,141 28,086 27,053 17,340
Profitability Ratio
ROA1 11.40% 9.75% 7.12% 5.92% 11.53%
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × 4,046 ÷ 35,480 = 11.40%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Celgene Corp. ROA improved from 2016 to 2017 and from 2017 to 2018.